AbbVie stock: Barclays raises target to USD 325 for AbbVie stock

Published on 10/23/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 16.99 billion, up 10.20 percent. AbbVie stock costs EUR 253.15 on October 23, 2026, down 0.22 percent versus Xetra close.

Analyst target raised

Barclays lifted its AbbVie target from USD 300.00 to USD 325.00 on October 21, 2026.
Quarterly revenue reached USD 16.99 billion, up 10.20 percent year over year.
AbbVie stock costs EUR 253.15 at Lang & Schwarz on October 23, 2026 at 3:39 p.m. CEST, 0.22 percent below the Xetra close of October 22, 2026.
AbbVie will report third-quarter 2026 results on October 30, 2026.
The company has a USD 501.4 billion market capitalization and a 79.88 earnings multiple.

Architektonischer 3D-Render eines modernen Pharmaforschungsgeländes mit Glasbauten und Grünanlagen — AbbVie Inc. US00287Y1091 Architektur Render moderner Pharma Forschungs Campus Glasbauten Grünanlagen aus Vogelperspektive, Illustration mit AI erstellt.

Barclays raised its AbbVie price target from USD 300.00 to USD 325.00 and maintained an overweight rating in a research note dated October 21, 2026, as MarketBeat reported. The target lies 14.54 percent above AbbVie's USD 283.74 US share price at 9:53 a.m. ET on October 23, 2026. AbbVie stock was trading at EUR 253.15 at Lang & Schwarz on October 23, 2026 at 3:39 p.m. CEST, down 0.22 percent versus the Xetra close of October 22, 2026.

Revenue reached USD 16.99 billion

AbbVie posted quarterly revenue of USD 16.99 billion for the period reported on July 31, 2026, up 10.20 percent from USD 15.41 billion in the comparable quarter, according to MarketBeat. The same report said adjusted earnings per share reached USD 3.65, beating the USD 3.61 consensus estimate by USD 0.04. The revenue figure gives the analyst target a measurable operating backdrop rather than leaving the valuation case dependent on sentiment alone.

Stock sits 2.63 percent below its high

The USD share price was USD 283.74 at 9:53 a.m. ET on October 23, 2026, down 0.51 percent from the prior US session. AbbVie traded within a USD 190.75 to USD 291.40 52-week range, placing the quote 2.63 percent below the high. The market capitalization was USD 501.4 billion, while the earnings multiple was 79.88.

October 30 results date

AbbVie will announce third-quarter 2026 results before the US market opens on October 30, 2026, and will hold its earnings call at 8:00 a.m. Central time, according to the company's AbbVie release dated October 1, 2026. The event is the next scheduled test for revenue growth, earnings delivery and the outlook that supports the current analyst range.

Market value and earnings multiple

AbbVie carries a larger market value than Amgen's USD 238.9 billion and Gilead Sciences' USD 194.8 billion, based on October 23, 2026 market figures. Its 79.88 earnings multiple also stands above Amgen's 27.41 multiple, while Gilead's multiple was negative. That contrast leaves the October 30 report important for testing whether the recent revenue increase can support the valuation.

Price remains below the yearly high

The euro quotation is 0.22 percent below the Xetra close of October 22, 2026, while the US listing remains 2.63 percent below its 52-week high. The different currencies describe separate venues and are not combined into one return calculation. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.